COPD patient with an exacerbating phenotype. Characterisation and treatment

Authors

  • Ramón Boixeda-Viu Servei de Medicina Interna, Hospital de Mataró, Mataró (Barcelona), Spain. Grupo de Trabajo de EPOC de la Sociedad Española de Medicina Interna

DOI:

https://doi.org/10.32818/reccmi.a2n3a17

Keywords:

chronic obstructive pulmonary disease, phenotypes COPD, bronchiectasis, treatment

Abstract

A 74-year-old man with a diagnosis of chronic bronchitis-type COPD with frequent exacerbations and persistent mucopurulent expectoration, who is admitted by a new acute exacerbation with mild hemoptotic sputum in which opportunistic infections are ruled out and a characterization of the phenotypes according to GesEPOC is performed and a readjustment of his treatment. The recent update of the GesEPOC guidelines advises a characterization of patients with COPD and high risk, stratifying the treatment and its management depending on the different phenotypes described.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Guía Española de la EPOC (GesEPOC). Versión 2017. Arch Bronconeumol. 2017; 53(Supl 1): 2-64.

Han MK, Agustí A, Calverley PM, Celli BR, Criner G, Curtis JL, et al. Chronic obstructive pulmonary disease phenotypes. The future of COPD. Am J Respir Crit Care Med. 2010; 182: 598-604.

Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010; 363: 1128-1138.

American Thoracic Society. Chronic bronchitis, asthma, and pulmonary emphysema, a statement by the Committee on Diagnostic Standards for Nontuberculous Respiratory Diseases. Am Rev Respir Dis. 1962; 85: 762-768.

Martínez-García F, Soler-Cataluña JJ, Donat Y, Catalán P, Agramunt M, Ballestin V, et al. Factors associated with bronchiectasis in chronic obstructive pulmonary disease patient. Chest. 2011; 140: 1130-1137.

Miravitlles M, Marin A, Monsó E, Vilà S, De la Roza C, Hervás R, et al. Colour of sputum is a marker for bacterial colonisation in chronic obstructive pulmonary disease. Respir Res. 2010; 11: 58.

Uzun S, Djamin RS, Kluytmans JA, Mulder PG, Van't Veer NE, Ermens AA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomized, double-blind, placebo-controlled trial. Lancet Respir Med. 2014; 2: 361-368.

Vendrell M, De Gracia J, Oliveira C, Martínez MA, Girón R, Máiz L, et al. Diagnóstico y tratamiento de las bronquiectasias. Arch Bronconeumol. 2008; 44: 629-640.

Published

2017-12-31

How to Cite

1.
Boixeda-Viu R. COPD patient with an exacerbating phenotype. Characterisation and treatment. Rev Esp Casos Clin Med Intern [Internet]. 2017 Dec. 31 [cited 2024 Dec. 26];2(3):152-4. Available from: https://www.reccmi.com/RECCMI/article/view/198